Immunophotonics and Swiss Cancer Institute Conclude Phase 1b/2a Clinical Trial for Cancer Treatment Immunophotonics, Inc. announces the completion of a significant clinical trial in collaboration with the Swiss Cancer Institute to treat advanced solid tumors.

Immunophotonics and Swiss Cancer Institute Conclude Phase 1b/2a Clinical Trial for Cancer Treatment #USA #St._Louis #Cancer_Institute #Immunophotonics #IP-001

Immunophotonics Completes Treatment Phase in Advanced Solid Tumor Trial with IP-001 Immunophotonics, Inc. announces the completion of patient treatments in the INJECTABL-1 trial for their innovative drug IP-001 for advanced solid tumors.

Immunophotonics Completes Treatment Phase in Advanced Solid Tumor Trial with IP-001 #USA #St._Louis #Clinical_Trials #Immunophotonics #IP-001